Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q1 FY23 results · Apr–Jun 2022
Cohance Lifesciences reported revenue from operations of ₹338.80 crore (up 28.4% from Q1 FY22) and net profit of ₹107.54 crore (up 2.3% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 338.80 | 263.80 | +28.4% | 363.85 | −6.9% |
| Other income | 11.03 | 5.78 | +90.8% | 16.87 | −34.6% |
| Total income | 349.83 | 269.58 | +29.8% | 380.72 | −8.1% |
| Profit before tax | 148.96 | 109.27 | +36.3% | 161.28 | −7.6% |
| Net profit for the period | 107.54 | 105.08 | +2.3% | 91.67 | +17.3% |
| EPS, basic (₹) | 4.22 | 4.13 | +2.2% | 3.60 | +17.2% |
| Net margin (%) | 31.7 | 39.8 | 25.2 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 338.80 | 263.80 | +28.4% | 363.85 | −6.9% |
| Other income | 10.90 | 5.78 | +88.4% | 134.40 | −91.9% |
| Total income | 349.70 | 269.58 | +29.7% | 498.24 | −29.8% |
| Profit before tax | 153.66 | 109.28 | +40.6% | 279.36 | −45.0% |
| Net profit for the period | 114.05 | 81.44 | +40.0% | 224.46 | −49.2% |
| EPS, basic (₹) | 4.48 | 3.20 | +40.0% | 8.82 | −49.2% |
| Net margin (%) | 33.7 | 30.9 | 61.7 |
Consolidated
- Filed with BSE
- 09 Aug 2022, 16:30 IST
- Board meeting
- 08 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Aug 2022, 16:30 IST
- Board meeting
- 08 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE